Skip to main content
Canna~Fangled Abstracts

Are CB2 Receptors a New Target for Schizophrenia Treatment?

By October 8, 2020December 17th, 2020No Comments
Review
. 2020 Oct 30;11:587154.

doi: 10.3389/fpsyt.2020.587154. eCollection 2020.

Isadora L Cortez 1, Naielly Rodrigues da Silva 1, Francisco S Guimarães 1, Felipe V Gomes 1
Affiliations 

Abstract

Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptors are now proposed to play a role in several brain processes related to schizophrenia, such as modulation of dopaminergic neurotransmission, microglial activation, and neuroplastic changes induced by stress. Here, we reviewed studies describing the involvement of the CB2 receptor in these processes and their association with the pathophysiology of schizophrenia. Taken together, these pieces of evidence indicate that CB2 receptor may emerge as a new target for the development of antipsychotic drugs.

 

Keywords: cannabinoids, dopamine, endocannabinoid system, microglia, psychosis

Figures

Figure 1

References

    1. Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Prim. (2015) 1:15067 10.1038/nrdp.2015.67 – DOI – PubMed
    1. Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet. (1995) 346:477–81. 10.1016/S0140-6736(95)91325-4 – DOI – PubMed
    1. Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. (2014) 19:38–52. 10.1017/S1092852914000601 – DOI – PubMed
    1. Murray RM, Lappin J, Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol. (2008) 18(Suppl 3):S129–34. 10.1016/j.euroneuro.2008.04.002 – DOI – PubMed
    1. Howes OD, McCutcheon R, Owen MJ, Murray RM. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. (2017) 81:9–20. 10.1016/j.biopsych.2016.07.014 – DOI – PMC – PubMed

Publication types

Leave a Reply